Opdivo plus chemo becomes first immunotherapy-based treatment to improve EFS and pCR in NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The neoadjuvant Opdivo (nivolumab) plus chemotherapy showed a statistically significant and clinically meaningful improvement in event-free survival compared to chemotherapy alone in patients with with resectable stage IB to IIIA non-small cell lung cancer, according to a prespecified interim analysis of the phase III CheckMate -816 trial. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The landscape of cancer care in America faces critical challenges: geographic disparities in access, socioeconomic barriers to advanced treatments and the increasing complexity of precision medicine that outpaces individual providers’ ability to stay current. At City of Hope, we are addressing these systemic issues through a bold expansion that brings world-class cancer care and research closer to where patients live.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login